Skip to main content
. 2019 May 8;21(8):1886–1894. doi: 10.1111/dom.13747

Table 2.

Percentages of patients achieving combined endpoints in the two groups

Combined endpoint Dapagliflozin (n = 473) GLP‐1RA (n = 336) P OR
Any reduction in HbA1c, BW and SBP, %
Unadjusted 31.3 29.8 0.642 1.05 (0.85–1.30)
MVA 29.9 31.7 0.631 0.91 (0.64–1.30)
PSM (average n = 229/group) 30.3 30.2 0.760 0.93 (0.61–1.44)
ΔHbA1c > 0.5%; ΔBW > 2 kg; ΔSBP>2 mm Hg, %
Unadjusted 16.9 17.3 0.897 0.98 (0.72–1.33)
MVA 16.0 18.6 0.397 0.82 (0.53–1.27)
PSM (average n = 229/group) 16.5 18.2 0.561 0.86 (0.53–1.41)
HbA1c ≤ 7.0%; ΔBW≥3%; SBP <140 mm Hg, %
Unadjusted 9.5 15.5 0.010 0.61 (0.42–0.89)
MVA 10.5 14.0 0.187 0.71 (0.44–1.15)
PSM (average n = 229/group) 12.6 17.7 0.183 0.70 (0.41–1.19)

Note: The three composite endpoints are given and data are reported for unadjusted analysis (percentages observed in the entire cohort), for multivariable adjustment (percentages estimated from regression models) and for propensity score‐matched analysis (percentages observed in matched groups).

Note: Multivariable adjustment included the following variables: age, sex, diabetes duration, HbA1c, eGFR, concomitant use of metformin and insulin.

Abbreviations: BW, body weight; BMI, fasting plasma glucose; OR, odds ratio; SBP, systolic blood pressure.